← Back to Search

Other

IMG-007 for Atopic Dermatitis/Eczema

Phase 1 & 2
Waitlist Available
Research Sponsored by Inmagene LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Male or female aged ≥ 18 and < 75 years
Documented history of inadequate response or lack of tolerability to a stable regimen of one or more topical treatment before the Screening visit, or for whom topical treatments are otherwise inadvisable
Must not have
Active infection requiring treatment with systemic antibiotics, antivirals, antifungals, antiparasitics or antiprotozoals at the Screening visit
Evidence of active or latent tuberculosis (TB)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, week 24

Summary

This trial tests IMG-007, a new drug, in adults with severe skin issues. It aims to see if the drug is safe and effective by administering it and monitoring its effects on the body and the skin condition.

Who is the study for?
Adults aged 18-75 with moderate-to-severe Atopic Dermatitis (AD) who haven't responded well to topical treatments can join this trial. Participants must not be pregnant or breastfeeding and agree to use effective contraception. Those with active infections, TB, hepatitis B/C, HIV, or other skin conditions that could affect the study's results are excluded.
What is being tested?
The trial is testing IMG-007 against a placebo in adults with AD. It aims to check how safe IMG-007 is, how the body processes it (pharmacokinetics), and if it's effective in improving symptoms of AD.
What are the potential side effects?
While specific side effects for IMG-007 aren't listed here, common ones for new AD treatments may include skin irritation at the application site, headaches, cold-like symptoms and possible allergic reactions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 18 and 75 years old.
Select...
Topical treatments have not worked for me or I cannot use them.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am not on treatment for an active infection with antibiotics or other similar drugs.
Select...
I have signs of active or dormant TB.
Select...
I have hepatitis B, C, or HIV.
Select...
I have had TB that was not treated or not treated well.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, week 24
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, week 24 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Evaluation of Adverse Events in Participants
Secondary study objectives
Evaluation of Eczema Area and Severity Index (EASI)
Pharmacokinetic Characterization

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: IMG-007 Dose 2Experimental Treatment1 Intervention
IMG-007 Dose 2 will be administered intravenously 3 times over 4 weeks
Group II: IMG-007 Dose 1Experimental Treatment1 Intervention
IMG-007 Dose 1 will be administered intravenously 3 times over 4 weeks
Group III: PlaceboPlacebo Group1 Intervention
Placebo will be administered intravenously 3 times over 4 weeks

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for eczema, such as phototherapy, melatonin, and barrier-strengthening moisturizers, work through different mechanisms to alleviate symptoms. Phototherapy, including UVB and UVA, reduces inflammation and modulates the immune response, which helps in decreasing the severity of eczema. Melatonin, known for its antioxidant and anti-inflammatory properties, can improve sleep and reduce disease severity. Barrier-strengthening moisturizers help maintain skin hydration and integrity, preventing flare-ups. Understanding these mechanisms is crucial for eczema patients as it helps in selecting appropriate treatments that target specific aspects of the disease, potentially improving outcomes and quality of life.
Combined UVB and UVA phototherapy of atopic eczema.Potential effects and mechanisms of Chinese herbal medicine in the treatment of psoriasis.Interventions for erythema multiforme: a systematic review.

Find a Location

Who is running the clinical trial?

Inmagene LLCLead Sponsor
5 Previous Clinical Trials
187 Total Patients Enrolled

Media Library

IMG-007 (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05984784 — Phase 1 & 2
Eczema Research Study Groups: Placebo, IMG-007 Dose 1, IMG-007 Dose 2
Eczema Clinical Trial 2023: IMG-007 Highlights & Side Effects. Trial Name: NCT05984784 — Phase 1 & 2
IMG-007 (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05984784 — Phase 1 & 2
~6 spots leftby Dec 2025